Project description
Real-world data to improve post-treatment in breast cancer
Meet REBECCA. This EU-funded project will use real-world data to improve post-treatment in breast cancer. It will also design guidelines and best practices for researchers and public health and regulatory bodies throughout Europe. As such, the project will move beyond the analysis of electronic health records, by combining this with detailed monitoring data from multiple wearables, online behaviour and registry data to monitor patients’ functional, emotional and quality of life trajectories. Specifically, REBECCA will focus on the complex array of chronic comorbidities developed during breast cancer recovery. However, the project will also demonstrate the extensibility of REBECCA to other forms of cancer. Findings will be disseminated widely to researchers and health bodies throughout Europe.
Objective
The REBECCA proposal aspires to tap into the potential of Real-world Data (RWD) for supporting groundbreaking clinical research on complex chronic conditions (CCC) as a complement to Randomised Controlled Trials (RCT). REBECCA moves beyond the analysis of Electronic health records (EHR), by combining it with detailed monitoring data from multiple wearable, online behaviour and registry data to monitor patients’ functional, emotional and Quality of Life trajectories, with high temporal granularity. REBECCA also proposes explainable causal modelling combined with deep learning to account for observed and latent confounders in RWD analysis. The project will focus on the complex array of chronic comorbidities developed during breast cancer recovery, in particular studying the impact of primary and adjuvant cancer treatment on patients’ quality of life and assessing the value of detailed patient monitoring as a means for improved patient care, but will also demonstrate the extensibility of REBECCA to other forms of cancer.
To this end, a total of seven studies in Sweden, Norway and Spain will produce new knowledge on clinical management of cancer patients that will shape future guidelines and practices for post-cancer treatments. Best practices resulting from the REBECCA studies will be disseminated to researchers, public health and regulatory bodies throughout Europe to facilitate wider adoption of RWD in clinical research. In addition, the REBECCA platform, capable of detailed monitoring and privacy-preserving federated cross-country data analysis, will provide an infrastructure for continued progress on use of RWD beyond the end of the project. Through these activities, REBECCA aims at the mass adoption of RWD for understanding CCCs and ultimately at establishing RWD as a valuable clinical research and patient management tool.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
546 36 THESSALONIKI
Greece